Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC
Shots:
- The companies reported that the proposed biosimilar MYL-1402O met predefined criteria for bio similarity to Avastin in a P-III trial in patients with stage IV non sq. NSCLC
- The study evaluated the efficacy, safety, and immunogenicity of MYL-1402O vs Avastin + CP CT in 671 patients with stage IV non sq. NSCLC for up to 18wks. (6 cycles), followed by monothx. with the reference drug or the biosimilar for up to 24wks.
- The study showed that the results were comparable between groups including PFS, OS, DCR & DOR; mPFS (7.6mos. vs 9.0mos); patient-reported at least 1 TEAEs (92.8% vs 92.4%)
Ref: Center for Biosimilars | Image: Viatris
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com